This study compares using a chemotherapy drug dacarbazine vs nivolumab (Optivo) with Wild Type Stage 3-4 melanoma adding to body of evidence that PD-1's have superior outcomes for overall survival to 5 years in melanoma patients, regardless of BRAF type. But we still have a long way to go. Overall survival rates for melanoma treatment using PD-1 immunotherapies are still only about 1/3 at 5 years post treatment initiation. Those with a complete response rate are more likely to be alive at the 5 year mark. #GetNaked to monitor your skin, and that of family. Donate to MRF, MRA, or AIM at Melanoma for research progress. Lobby your federal legislators to continue research and clinical trials for melanoma. Be well.
medpagetoday.com/hematology...
Peace,
missy
